A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01427933. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
Study identification
- NCT ID
- NCT01427933
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 141 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2011 (Type not available)
- Primary completion
- Sep 2013 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Feb 6, 2017
2011 – 2014
United States locations
- U.S. sites
- 52
- U.S. states
- 24
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Birmingham | Alabama | 35211 | — |
| ImClone Investigational Site | Gilroy | California | 95020 | — |
| ImClone Investigational Site | Palm Springs | California | 92262 | — |
| ImClone Investigational Site | Denver | Colorado | 80220 | — |
| ImClone Investigational Site | Southington | Connecticut | 06489 | — |
| ImClone Investigational Site | Fort Myers | Florida | 33916 | — |
| ImClone Investigational Site | Jacksonville | Florida | 32207 | — |
| ImClone Investigational Site | Orlando | Florida | 32806 | — |
| ImClone Investigational Site | Plantation | Florida | 33324 | — |
| ImClone Investigational Site | Port Saint Lucie | Florida | 34952 | — |
| ImClone Investigational Site | St. Petersburg | Florida | 33705 | — |
| ImClone Investigational Site | Tampa | Florida | 33612 | — |
| ImClone Investigational Site | Albany | Georgia | 31701 | — |
| ImClone Investigational Site | Lawrenceville | Georgia | 30046 | — |
| ImClone Investigational Site | Park Ridge | Illinois | 60068 | — |
| ImClone Investigational Site | Columbia | Maryland | 21044 | — |
| ImClone Investigational Site | Rockville | Maryland | 20850 | — |
| ImClone Investigational Site | Dearborn | Michigan | 48126 | — |
| ImClone Investigational Site | Minneapolis | Minnesota | 55404 | — |
| ImClone Investigational Site | Saint Joseph | Missouri | 64507 | — |
| ImClone Investigational Site | St Louis | Missouri | 63110 | — |
| ImClone Investigational Site | Henderson | Nevada | 89074 | — |
| ImClone Investigational Site | Morristown | New Jersey | 07960 | — |
| ImClone Investigational Site | Johnson City | New York | 13790 | — |
| ImClone Investigational Site | Lake Success | New York | 11042 | — |
| ImClone Investigational Site | The Bronx | New York | 10469 | — |
| ImClone Investigational Site | Burlington | North Carolina | 27215 | — |
| ImClone Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| ImClone Investigational Site | Dayton | Ohio | 45429 | — |
| ImClone Investigational Site | Middletown | Ohio | 45042 | — |
| ImClone Investigational Site | Toledo | Ohio | 43623 | — |
| ImClone Investigational Site | Portland | Oregon | 97213 | — |
| ImClone Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| ImClone Investigational Site | Charleston | South Carolina | 29414 | — |
| ImClone Investigational Site | Greenville | South Carolina | 29605 | — |
| ImClone Investigational Site | Chattanooga | Tennessee | 37404 | — |
| ImClone Investigational Site | Nashville | Tennessee | 37203 | — |
| ImClone Investigational Site | Arlington | Texas | 76014 | — |
| ImClone Investigational Site | Bedford | Texas | 76022 | — |
| ImClone Investigational Site | Dallas | Texas | 75246 | — |
| ImClone Investigational Site | Fort Worth | Texas | 76104 | — |
| ImClone Investigational Site | Houston | Texas | 77024 | — |
| ImClone Investigational Site | Plano | Texas | 75075 | — |
| ImClone Investigational Site | San Antonio | Texas | 78217 | — |
| ImClone Investigational Site | The Woodlands | Texas | 77380 | — |
| ImClone Investigational Site | Tyler | Texas | 75702 | — |
| ImClone Investigational Site | Rutland | Vermont | 05701 | — |
| ImClone Investigational Site | Fairfax | Virginia | 22031 | — |
| ImClone Investigational Site | Norfolk | Virginia | 23502 | — |
| ImClone Investigational Site | Richmond | Virginia | 23230 | — |
| ImClone Investigational Site | Salem | Virginia | 24153 | — |
| ImClone Investigational Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01427933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2017 · Synced Nov 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.